Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)Dilazep: Coronary vasodilator with some antiarrhythmic activity.Adenosine: A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.Vasodilator Agents: Drugs used to cause dilation of the blood vessels.Thioinosine: Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503)Thallium Radioisotopes: Unstable isotopes of thallium that decay or disintegrate emitting radiation. Tl atoms with atomic weights 198-202, 204, and 206-210 are thallium radioisotopes.Coronary Circulation: The circulation of blood through the CORONARY VESSELS of the HEART.Equilibrative-Nucleoside Transporter 2: A subtype of equilibrative nucleoside transporter proteins that is insensitive to inhibition by 4-nitrobenzylthioinosine.Equilibrative Nucleoside Transporter 1: A subtype of equilibrative nucleoside transporter proteins that is sensitive to inhibition by 4-nitrobenzylthioinosine.Nucleosides: Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed)Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.Nitrogen Radioisotopes: Unstable isotopes of nitrogen that decay or disintegrate emitting radiation. N atoms with atomic weights 12, 13, 16, 17, and 18 are radioactive nitrogen isotopes.Exercise Test: Controlled physical activity which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used.Technetium Tc 99m Sestamibi: A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.Thallium: A heavy, bluish white metal, atomic number 81, atomic weight [204.382; 204.385], symbol Tl.Heart: The hollow, muscular organ that maintains the circulation of the blood.Theophylline: A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP.Tomography, Emission-Computed, Single-Photon: A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image.Nucleoside Transport Proteins: Proteins involved in the transport of NUCLEOSIDES across cellular membranes.Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.Tomography, Emission-Computed: Tomography using radioactive emissions from injected RADIONUCLIDES and computer ALGORITHMS to reconstruct an image.Platelet Aggregation Inhibitors: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.Phosphodiesterase Inhibitors: Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.Rubidium Radioisotopes: Unstable isotopes of rubidium that decay or disintegrate emitting radiation. Rb atoms with atomic weights 79-84, and 86-95 are radioactive rubidium isotopes.Echocardiography, Stress: A method of recording heart motion and internal structures by combining ultrasonic imaging with exercise testing (EXERCISE TEST) or pharmacologic stress.Hyperemia: The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).Echocardiography: Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.Lidoflazine: Coronary vasodilator with some antiarrhythmic action.Equilibrative Nucleoside Transport Proteins: A class of sodium-independent nucleoside transporters that mediate the facilitative transport of NUCLEOSIDES.2-Chloroadenosine: 2-Chloroadenosine. A metabolically stable analog of adenosine which acts as an adenosine receptor agonist. The compound has a potent effect on the peripheral and central nervous system.Inosine: A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)Blood Vessels: Any of the tubular vessels conveying the blood (arteries, arterioles, capillaries, venules, and veins).Platelet Aggregation: The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.Capsules: Hard or soft soluble containers used for the oral administration of medicine.Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Vasodilation: The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE.Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.Breast Neoplasms: Tumors or cancer of the human BREAST.Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.Receptors, Progesterone: Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.LymphangitisErysipelas: An acute infection of the skin caused by species of STREPTOCOCCUS. This disease most frequently affects infants, young children, and the elderly. Characteristics include pink-to-red lesions that spread rapidly and are warm to the touch. The commonest site of involvement is the face.Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.Heart, Artificial: A pumping mechanism that duplicates the output, rate, and blood pressure of the natural heart. It may replace the function of the entire heart or a portion of it, and may be an intracorporeal, extracorporeal, or paracorporeal heart. (Dorland, 28th ed)Heart Valves: Flaps of tissue that prevent regurgitation of BLOOD from the HEART VENTRICLES to the HEART ATRIA or from the PULMONARY ARTERIES or AORTA to the ventricles.Heart Valve Prosthesis: A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material.Heart Valve Prosthesis Implantation: Surgical insertion of synthetic material to repair injured or diseased heart valves.Aortic Valve: The valve between the left ventricle and the ascending aorta which prevents backflow into the left ventricle.Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).

Primary biliary cirrhosis associated with membranous glomerulonephritis. (1/980)

A 33-year-old woman was admitted to our department for evaluation of liver dysfunction and proteinuria. A liver biopsy specimen showed ductular proliferation and moderate portal fibrosis indicating stage II primary biliary cirrhosis. A renal biopsy specimen showed mild to moderate mesangial cell proliferation without crescent formation or interstitial nephritis. Immunofluorescent staining revealed deposition of immunoglobulin G (IgG), third component of complement (C3), and Clq on glomerular basement membranes. The findings indicated stage I membranous glomerulonephritis. Administration of ursodesoxycholic acid together with prednisolone, azathioprine, and dipyridamole decreased proteinuria and improved cholestatic liver dysfunction.  (+info)

Integrated evaluation of relation between coronary lesion features and stress echocardiography results: the importance of coronary lesion morphology. (2/980)

OBJECTIVES: The aim of this study was to analyze, in the same group of patients, the relationship between multiple variables of coronary lesion and results of exercise, dobutamine and dipyridamole stress echocardiography tests. BACKGROUND: Integrated evaluation of the relation between stress echocardiography results and angiographic variables should include not only the assessment of stenosis severity but also evaluation of other quantitative and qualitative features of coronary stenosis. METHODS: Study population consisted of 168 (138 male, 30 female, mean age 51+/-9 years) patients, on whom exercise (Bruce treadmill protocol), dobutamine (up to 40 mcg/kg/min) and dipyridamole (0.84 mg/kg over 10 min) stress echocardiography tests were performed. Stress echocardiography test was considered positive for myocardial ischemia when a new wall motion abnormality was observed. One-vessel coronary stenosis ranging from mild stenosis to complete obstruction of the vessel was present in 153 patients, and 15 patients had normal coronary arteries. The observed angiographic variables included particular coronary vessel, stenosis location, the presence of collaterals, plaque morphology according to Ambrose classification, percent diameter stenosis and obstruction diameter as assessed by quantitative coronary arteriography. RESULTS: Covariates significantly associated with the results of physical and pharmacological stress tests included for all three stress modalities presence of collateral circulation, percent diameter stenosis and obstruction diameter, as well as lesion morphology (p < 0.05 for all, except collaterals for dobutamine stress test, p = 0.06). By stepwise multiple logistic regression analysis, the strongest predictor of the outcome of exercise echocardiography test was only percent diameter stenosis (p = 0.0002). However, both dobutamine and particularly dipyridamole stress echocardiography results were associated not only with stenosis severity - percent diameter stenosis (dobutamine, p = 0.04; dipyridamole, p = 0.003) - but also, and even more strongly, with lesion morphology (dobutamine, p = 0.006; dipyridamole, p = 0.0009). As all of stress echocardiography results were significantly associated with percent diameter stenosis, the best angiographic cutoff in relation to the results of stress echocardiography test was: exercise, 54%; dobutamine, 58% and dipyridamole, 60% (p < 0.05 vs. exercise). CONCLUSIONS: Integrated evaluation of angiographic variables have shown that the results of dobutamine and dipyridamole stress echocardiography are not only influenced by stenosis severity but also, and even more importantly, by plaque morphology. The results of exercise stress echocardiography, although separately influenced by plaque morphology, are predominantly influenced by stenosis severity, due to a stronger exercise capacity in provoking myocardial ischemia in milder forms of coronary stenosis.  (+info)

Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q). (3/980)

We have produced recombinant human equilibrative nucleoside transporter (hENT1) in the yeast Saccharomyces cerevisiae and have compared the binding of inhibitors of equilibrative nucleoside transport with the wild-type transporter and a N-glycosylation-defective mutant transporter. Equilibrium binding of 3H-labelled nitrobenzylmercaptopurine ribonucleoside {6-[(4-nitrobenzyl)thio]-9-beta-d-ribofuranosyl purine; NBMPR} to hENT1-producing yeast revealed a single class of high-affinity sites that were shown to be in membrane fractions by (1) equilibrium binding (means+/-S.D.) of [3H]NBMPR to intact yeast (Kd 1.2+/-0.2 nM; Bmax 5.0+/-0.5 pmol/mg of protein) and membranes (Kd 0.7+/-0.2 nM; Bmax 6.5+/-1 pmol/mg of protein), and (2) reconstitution of hENT1-mediated [3H]thymidine transport into proteoliposomes that was potently inhibited by NBMPR. Dilazep and dipyridamole inhibited NBMPR binding to hENT1 with IC50 values of 130+/-10 and 380+/-20 nM respectively. The role of N-linked glycosylation in the interaction of NBMPR with hENT1 was examined by the quantification of binding of [3H]NBMPR to yeast producing either wild-type hENT1 or a glycosylation-defective mutant (hENT1/N48Q) in which Asn-48 was converted into Gln. The Kd for binding of NBMPR to hENT1/N48Q was 10. 5+/-1.6 nM, indicating that the replacement of an Asn residue with Gln decreased the affinity of hENT1 for NBMPR. The decreased affinity of hENT1/N48Q for NBMPR was due to an increased rate of dissociation (koff) and a decreased rate of association (kon) of specifically bound [3H]NBMPR because the values for hENT1-producing and hENT1/N48Q-producing yeast were respectively 0.14+/-0.02 and 0. 36+/-0.05 min-1 for koff, and (1.2+/-0.1)x10(8) and (0.40+/-0. 04)x10(8) M-1.min-1 for kon. These results indicated that the conservative conversion of an Asn residue into Gln at position 48 of hENT1 and/or the loss of N-linked glycosylation capability altered the binding characteristics of the transporter for NBMPR, dilazep and dipyridamole.  (+info)

Coronary flow reserve in young men with familial combined hyperlipidemia. (4/980)

BACKGROUND: Familial combined hyperlipidemia (FCHL) is a common hereditary disorder of lipoprotein metabolism estimated to cause 10% to 20% of premature coronary heart disease. We investigated whether functional abnormalities exist in coronary reactivity in asymptomatic patients with FCHL. METHODS AND RESULTS: We studied 21 male FCHL patients (age, 34.8+/-5.4 years) and a matched group of 21 healthy control subjects. Myocardial blood flow (MBF) was measured at baseline and during dipyridamole-induced hyperemia with PET and 15O-labeled water. The baseline MBF was similar in patients and control subjects (0.79+/-0.19 versus 0.88+/-0.20 mL. g-1. min-1, P=NS). An increase in MBF was seen in both groups after dipyridamole infusion, but MBF at maximal vasodilation was lower in FCHL patients (3.54+/-1.59 versus 4.54+/-1.17 mL. g-1. min-1, P=0.025). The difference in coronary flow reserve (CFR) was not statistically significant (4.7+/-2.2 versus 5.3+/-1.6, P=NS, patients versus control subjects). Considerable variability in CFR values was detected within the FCHL group. Patients with phenotype IIB (n=8) had lower flow during hyperemia (2.5+/-1.2 versus 4.2+/-1.5 mL. g-1. min-1, P<0.05) and lower CFR (3.4+/-2.1 versus 5.4+/-2.0, P<0.05) compared with phenotype IIA (n=13). CONCLUSIONS: Abnormalities in coronary flow regulation exist in young asymptomatic FCHL patients expressing phenotype IIB (characterized by abnormalities in both serum cholesterol and triglyceride concentrations). This is in line with previous observations suggesting that the metabolic abnormalities related to the pathophysiology of FCHL are associated with the phenotype IIB.  (+info)

Phasic coronary flow pattern and flow reserve in patients with left bundle branch block and normal coronary arteries. (5/980)

OBJECTIVES: The purpose of this study was to determine whether scintigraphic myocardial perfusion defects in patients with left bundle branch block (LBBB) and normal coronary arteries are related to abnormalities in coronary flow velocity pattern and/or coronary flow reserve. BACKGROUND: Septal or anteroseptal defects on exercise myocardial perfusion scintigraphy are common in patients with LBBB and normal coronary arteries. METHODS: Thirteen patients (7 men, age 61+/-8 years) with LBBB and normal coronary arteries underwent stress thallium-201 scintigraphy and cardiac catheterization. In all patients and in 11 control subjects coronary blood flow parameters were calculated from Doppler measurements of flow velocity in the left anterior descending coronary artery (LAD) before and after adenosine administration. RESULTS: The time to maximum peak diastolic flow velocity was significantly longer both for the seven patients with (134+/-19 ms) and for the six without (136+/-7 ms) exercise perfusion defects than for controls (105+/-12 ms, p < 0.05), whereas the acceleration was slower (170+/-54, 186+/-42 and 279+/-96 cm/s2, respectively, p < 0.05). Coronary flow reserve in the patients with exercise perfusion defects (2.7+/-0.3) was significantly lower than in those without (3.7+/-0.5, p < 0.05) or in the control group (3.4+/-0.5, p < 0.05). CONCLUSIONS: Patients with LBBB have an impairment of early diastolic blood flow in the LAD due to an increase in early diastolic compressive resistance resulting from delayed ventricular relaxation. Furthermore, exercise scintigraphic perfusion defects in these patients are associated with a reduced coronary flow reserve, indicating abnormalities of microvascular function in the same vascular territory.  (+info)

Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with syndrome X. (6/980)

BACKGROUND: Impaired vasodilatation capacity in patients with angina pectoris and a normal coronary arteriogram (syndrome X [SX]) has been reported. Most studies report on the response in epicardial vessels. This does not necessarily reflect compromised myocardial microcirculation. Lack of the NO precursor L-arginine has been suggested as a possible cause. METHODS AND RESULTS: Myocardial blood flow (MBF) was measured, using PET, at rest (MBF-rest) and during intravenous dipyridamole (MBF-DIP) in 25 women (mean age 53+/-7 years) with SX. Thirty healthy volunteers served as controls. One group (A) consisted of 15 age-matched female volunteers (54+/-10 years). The other control group consisted of 15 young healthy women (B; 24+/-5 years). In 12 SX patients, MBF-rest and MBF during cold pressor testing were also measured after infusion of L-arginine (6.7 g/min for 45 minutes). The increase in MBF after cold pressor testing was similar in the SX group compared with controls. L-arginine did not affect MBF-rest (0.83+/-0.14 versus 0.89+/-0.13 mL. g-1. min-1) or MBF after cold pressor test (0.95+/-0.10 versus 1. 03+/-0.17 mL. g-1min-1). In contrast, the hyperemic response to DIP was blunted compared with the group A controls (1.68+/-0.49 versus 2. 34+/-0.45 mL. g-1. min-1, P<0.05); this resulted in a significant reduction of the coronary flow reserve in SX patients relative to controls (2.03+/-0.53 versus 2.96+/-0.63 mL. g-1. min-1, P<0.01). CONCLUSIONS: In patients with SX, the microcirculatory response to cold, reflecting the endothelium function, is normal and unaltered by intravenous L-arginine. This suggests preserved microcirculatory endothelial function. However, a markedly attenuated hyperemic flow and flow reserve after DIP suggest a dysfunction of the adenosine-mediated endothelium-independent vasodilatation at the microcirculatory level in these patients.  (+info)

Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. (7/980)

BACKGROUND: Inhibitors of adenosine membrane transport cause vasodilation and enhance the plasma adenosine concentration. However, it is unclear why the plasma adenosine concentration rises rather than falls when membrane transport is inhibited. We tested the hypothesis that the cytosolic adenosine concentration exceeds the interstitial concentration under well-oxygenated conditions. METHODS AND RESULTS: In isolated, isovolumically working guinea pig hearts (n=50), the release rate of adenosine and accumulation of S-adenosylhomocysteine (after 20 minutes of 200 micromol/L homocysteine), a measure of the free cytosolic adenosine concentration, were determined in the absence and presence of specific and powerful blockers of adenosine membrane transport (nitrobenzylthioinosine 1 micromol/L), adenosine deaminase (erythro-9-hydroxy-nonyl-adenine 5 micromol/L), and adenosine kinase (iodotubericidine 10 micromol/L). Data analysis with a distributed multicompartment model revealed a total cardiac adenosine production rate of 2294 pmol. min-1. g-1, of which 8% was produced in the extracellular region. Because of a high rate of intracellular metabolism, however, 70.3% of extracellularly produced adenosine was taken up into cellular regions, an effect that was effectively eliminated by membrane transport block. The resulting approximately 2.8-fold increase of the interstitial adenosine concentration evoked near-maximal coronary dilation. CONCLUSIONS: We rejected the hypothesis that the cytosolic adenosine concentration exceeds the interstitial. Rather, there is significant extracellular production, and the parenchymal cell represents a sink, not a source, for adenosine under well-oxygenated conditions.  (+info)

Effects of sevoflurane on regional myocardial blood flow distribution: quantification with myocardial contrast echocardiography. (8/980)

BACKGROUND: Using myocardial contrast echocardiography, the authors tried to determine whether sevoflurane causes myocardial blood maldistribution in humans and dogs. METHODS: In animal experiments, 15 mongrel dogs were organized into dipyridamole (n = 6) and sevoflurane (n = 9) groups. Sonicated albumin was infused into the left main coronary artery. The peak gray level corrected for background was analyzed at the following intervals: (1) at baseline, (2) after stenosis of the left circumflex coronary artery (blood flow reduced by 40%), (3) after administration of dipyridamole (1 mg/kg given intravenously) or sevoflurane (1 minimum alveolar concentration) during stenosis, and (4) after phenylephrine during stenosis and administration of dipyridamole or sevoflurane. In human studies, nine patients undergoing coronary artery bypass grafting were studied. During partial extracorporeal circulation, the peak gray level was analyzed before and 20 min after sevoflurane (1 minimum alveolar concentration). RESULTS: In animal experiments, dipyridamole decreased significantly the inner:outer ratio of the peak gray level in the ischemic area and the ischemic:normal ratio of the peak gray level. After arterial pressure was restored with phenylephrine, neither the inner:outer ratio nor the ischemic:normal ratio improved. In contrast, after sevoflurane administration, the inner:outer ratio and the ischemic:normal ratio remained unchanged, but these increased with phenylephrine. In human studies, sevoflurane did not change the inner:outer ratio in the area supplied by the most stenotic coronary artery. CONCLUSION: These results suggest that dipyridamole, a potent coronary vasodilator, produces maldistribution of coronary blood flow in our dog models, whereas sevoflurane does not do this in animal or human studies.  (+info)

  • Dipyridamole (trademarked as Persantine and others) is a medication that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time. (wikipedia.org)
  • Persantine (dipyridamole USP) is a platelet inhibitor chemically described as 2,2',2'',2'''-[(4,8- Dipiperidinopyrimido[5,4- d ]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. (rxlist.com)
  • What are the possible side effects of dipyridamole (Persantine)? (rxlist.com)
  • Persantine (dipyridamole USP) tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement. (rxlist.com)
  • PERSANTINE (dipyridamole USP) tablets are available as round, orange, sugar-coated tablets of 25 mg, 50 mg and 75 mg coded BI/17, BI/18 and BI/19, respectively. (rxlist.com)
  • On long-term use of Persantine (dipyridamole USP) tablets initial side effects usually disappear. (rxlist.com)
  • When Persantine (dipyridamole) tablets were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. (rxlist.com)
  • No pharmacokinetic drug-drug interaction studies were conducted with Persantine (dipyridamole USP) Tablets. (rxlist.com)
  • You'll see a resurgence in using dipyridamole (Persantine, etc) with ASA to prevent stroke. (therapeuticresearch.com)
  • Dipyridamole is used to dilate blood vessels in people with peripheral arterial disease and coronary artery disease Dipyridamole has been shown to lower pulmonary hypertension without significant drop of systemic blood pressure It inhibits formation of pro-inflammatory cytokines (MCP-1, MMP-9) in vitro and results in reduction of hsCRP in patients. (wikipedia.org)
  • A triple therapy of aspirin, clopidogrel, and dipyridamole has been investigated, but this combination led to an increase in adverse bleeding events. (wikipedia.org)
  • Dipyridamole inhibits the phosphodiesterase enzymes that normally break down cAMP (increasing cellular cAMP levels and blocking the platelet aggregation response to ADP) and/or cGMP. (wikipedia.org)
  • Dipyridamole absorption is pH-dependent and concomitant treatment with gastric acid suppressors (such as a proton pump inhibitor) will inhibit the absorption of liquid and plain tablets. (wikipedia.org)
  • However, it is not licensed as monotherapy for stroke prophylaxis, although a Cochrane Review suggested that dipyridamole may reduce the risk of further vascular events in patients presenting after cerebral ischemia. (wikipedia.org)
  • The Persantin retard brand of dipyridamole is also prescribed to people who have already suffered a stroke or mini-stroke (transient ischaemia attack or TIA) to prevent blood clots causing further strokes. (netdoctor.co.uk)
  • Likewise, it is not uncommon to see Dipyridamole prescribed for adults in the prevention of stroke. (suite101.net)
  • DIPYRIDAMOLE is used to decrease the risk of stroke in patients who have had a stroke or transient ischemic attack. (tab-advice.com)
  • CONCLUSIONS: One week of oral treatment with the nucleoside uptake inhibitor dipyridamole (200 mg, slow release, twice daily) significantly limits ischemia-reperfusion injury in humans in vivo, as assessed by technetium Tc 99m-labeled annexin A5 scintigraphy of forearm skeletal muscle. (ru.nl)
  • We enrolled 161 patients referred for stress echocardiography (exercise 115, dipyridamole 40, pacing 6 patients).The sensor was fastened in the precordial region by a standard ECG electrode. (nih.gov)
  • Dipyridamole is a widely prescribed drug in ischemic disorders, and it is here investigated for potential clinical use as a new treatment for breast cancer. (springer.com)
  • We suggest that when used at appropriate doses and with the correct mode of administration, dipyridamole is a promising agent for breast-cancer treatment, thus also implying its potential use in other cancers that show those highly activated pathways. (springer.com)
  • Dipyridamole is used to dilate blood vessels in people with peripheral arterial disease and coronary artery disease Dipyridamole has been shown to lower pulmonary hypertension without significant drop of systemic blood pressure It inhibits formation of pro-inflammatory cytokines (MCP-1, MMP-9) in vitro and results in reduction of hsCRP in patients. (wikipedia.org)
  • Dipyridamole is a potent coronary arteriolar vasodilator that has been employed in combination with thallium-201 imaging for the detection of coronary artery disease. (springer.com)
  • Picano E, Lattanzi F, Masini M, Distante A, L'Abbate A (1988) Usefulness of the dipyridamole-exercise echocardiography test for diagnosis of coronary artery disease. (springer.com)
  • 4 5 6 7 8 9 10 While dipyridamole has been widely used for the measurement of coronary flow reserve in patients with coronary artery disease as well as coronary risk factors, 3 it has been reported that coronary atherosclerosis was a important potential risk factor for silent brain infarction. (ahajournals.org)
  • Dipyridamole is used for evaluating coronary artery disease in patients who cannot exercise adequately before thallium imaging (cardiac blood flow scan). (silverpharmacy.com)
  • The authors conclude that the presence and severity of ischemic coronary artery disease may be underestimated in patients receiving beta-blocker therapy while undergoing dipyridamole stress myocardial perfusion imaging. (onlinejacc.org)
  • Ever since I started dipyridamole 100mg pills $120.00 building LeafSeek almost nine months ago, I have been looking forward to the day when I could finally release the software publicly dipyridamole 100mg pills $120.00 , so that other people and organizations could use the awesome power of Apache Solr and the flexibility of the Solarium Project to present online databases to their users. (leafseek.com)
  • Dipyridamole 100mg pills $120.00 and now that day is here! (leafseek.com)
  • See "Dipyridamole Precautions" section. (rxwiki.com)
  • Dipyridamole is also available without a brand name, ie as the generic medicine. (netdoctor.co.uk)
  • The infections were usually mild and consistent CHAPTER 45 IMMUNOSUPPRESSANTS 685 with those commonly seen in outpatient pediatric settings generic dipyridamole 25 mg fast delivery hypertension synonym. (pili.org)
  • METHODS: The effect of dipyridamole and the calcium channel blockers on mitoxantrone efflux by BCRP-overexpressing human embryonic kidney (HEK) cells was determined by flow cytometry. (biomedsearch.com)
  • However, it is not licensed as monotherapy for stroke prophylaxis, although a Cochrane Review suggested that dipyridamole may reduce the risk of further vascular events in patients presenting after cerebral ischemia. (wikipedia.org)
  • The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or stroke. (clinicaltrials.gov)
  • Dipyridamole is primarily used in the prevention of blood clotting in patients, and it finds wide application after surgeries. (suite101.net)
  • The purpose of this study is to determine the benefits as well as side effects of giving drugs called dipyridamole and magnesium to patients with sickle cell anemia (SCA). (clinicaltrials.gov)
  • Picano E, Masini M, Lattanzi F, Klassen GA, Distante A, Levantesi D, Marraccini P, L'Abbate A (1988) Short term reproducibility of exercise testing in patients with ST segment elevation and different responses to the dipyridamole test. (springer.com)
  • 13 Therefore, dipyridamole stress tests to estimate coronary flow reserve are often performed in patients highly at risk for cerebrovascular diseases, and cerebrovascular accidents during dipyridamole stress tests have been reported. (ahajournals.org)
  • A considerable proportion of patients discontinue dipyridamole therapy because of headache. (ebscohost.com)
  • The study randomized 2700 patients to aspirin with or without dipyridamole following a minor stroke or transient ischemic attack. (ebscohost.com)
  • As a result, dipyridamole supplementation was associated with significantly decreased concentrations of D-dimers, increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. (medicalxpress.com)
  • A peroral form causes less side effects and patients feel better than using injections with Dipyridamole. (rxmedscanada.com)
  • Of the 21 CCVI patients, pentoxifylline (POX) was administered to 9, dipyridamole (DIP) to 6 and POX+DIP to another 6. (iospress.com)
  • Aspirin/dipyridamole reduces the risk of stroke in patients who have had or are at risk of stroke. (medicap.com)
  • Although heart rate did increase significantly in placebo-treated patients with dipyridamole infusion in the Taillefer et al. (onlinejacc.org)
  • This study compared the use of dobutamine and dipyridamole in cardiac stress testing of patients on hemodialysis. (nephrologynow.com)
  • DIPYRIDAMOLE (dye peer ID a mole) is used in patients who have had heart valve replacements. (oumedicine.com)
  • Cariprazine: (Moderate) Orthostatic vital signs should be monitored in patients who are at risk for hypotension, dipyridamole ccb such as those receiving cariprazine in combination with antihypertensive agents! (ezaxessloans.com)
  • Dipyridamole is a widely prescribed drug in ischemic disorders, and it is here investigated for potential clinical use as a new treatment for breast cancer. (springer.com)
  • In this piece, we take a holistic look at Dipyridamole, exploring everything you have ever wanted to know about the drug. (suite101.net)
  • Is dipyridamole drug safe for women who are pregnant or breastfeeding? (healthtap.com)
  • Dipyridamole is a drug which can cause increased bleeding and bruising, and beer is the last place it should be. (healthtap.com)
  • It seems safe in longitudinal studies of women on it, dipyridamole eye drops buy but it is listed in the PDR as a drug to avoid unless the depression won't allow it. (samhaskinsblog.com)
  • By virtual screening of a U.S. FDA approved drug library, the authors identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication invitro. (medicalxpress.com)
  • Pregnant women should only take Dipyridamole when absolutely necessary and should consult with a doctor before breast feeding, since the drug can be transferred via breast milk. (rpspharmacy.com)
  • It is a must to let your doctors know about the usage of this drug before going under any surgical procedure since Dipyridamole has the tendency to increase bleeding. (rpspharmacy.com)
  • NDA 078804 describes ASPIRIN AND DIPYRIDAMOLE , which is a drug marketed by Amneal Pharms , Barr , Impax Labs Inc , Par Pharm Inc , Sandoz Inc , and Zydus Pharms Usa Inc , and is included in six NDAs. (drugpatentwatch.com)
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE (capsule) | Top Interaction Warnings  | Healthgrades.com
ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE (capsule) | Top Interaction Warnings | Healthgrades.com (healthgrades.com)
Lopressor (Metoprolol Tartrate): Uses, Dosage, Side Effects, Interactions, Warning
Lopressor (Metoprolol Tartrate): Uses, Dosage, Side Effects, Interactions, Warning (rxlist.com)
Persantin (dipyridamole)
Persantin (dipyridamole) (netdoctor.co.uk)
Transient Ischemic Attack Medication: Antiplatelet Agents, Anticoagulants
Transient Ischemic Attack Medication: Antiplatelet Agents, Anticoagulants (emedicine.medscape.com)
Persantin retard (dipyridamole)
Persantin retard (dipyridamole) (netdoctor.co.uk)
DailyMed - METOPROLOL TARTRATE- metoprolol tartrate tablet, film coated
DailyMed - METOPROLOL TARTRATE- metoprolol tartrate tablet, film coated (dailymed.nlm.nih.gov)
Dipyridamole (webbook.nist.gov)
Asasantin retard (aspirin, dipyridamole)
Asasantin retard (aspirin, dipyridamole) (netdoctor.co.uk)
Dipyridamole prevents triple-negative breast-cancer progression | SpringerLink
Dipyridamole prevents triple-negative breast-cancer progression | SpringerLink (link.springer.com)
Dipyridamole - Side Effects, Dosage, Interactions - Drugs - Everyday Health
Dipyridamole - Side Effects, Dosage, Interactions - Drugs - Everyday Health (everydayhealth.com)
Drug Shortage Detail: Dipyridamole Injection
Drug Shortage Detail: Dipyridamole Injection (ashp.org)
How Much Aspirin and Dipyridamole online - Fast Delivery - 100% Satisfaction Guaranteed
How Much Aspirin and Dipyridamole online - Fast Delivery - 100% Satisfaction Guaranteed (thehivedxb.com)
Drug Information
Drug Information (medindia.net)
Dipyridamole 100 mg, 25 mg. Trusted online Dipyridamole OTC.
Dipyridamole 100 mg, 25 mg. Trusted online Dipyridamole OTC. (pili.org)
September 1987 - Volume 12 - Issue 9S : Clinical Nuclear Medicine
September 1987 - Volume 12 - Issue 9S : Clinical Nuclear Medicine (journals.lww.com)
Complete Guide to Prescription & Nonprescription Drugs 2011 - H. Winter Griffith - Google Books
Complete Guide to Prescription & Nonprescription Drugs 2011 - H. Winter Griffith - Google Books (books.google.com)
Buy Generic for Asasantin 100mg and Save $52.47
Buy Generic for Asasantin 100mg and Save $52.47 (internationaldrugmart.com)
Dipyridamole: MedlinePlus Drug Information
Dipyridamole: MedlinePlus Drug Information (medlineplus.gov)
Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution...
Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution... (onlinelibrary.wiley.com)
High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia...
High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia... (dmm.biologists.org)
All You Need to Know About Dipyridamole
All You Need to Know About Dipyridamole (suite101.net)
Which antiplatelet agents are used for the treatment of middle cerebral artery (MCA) stroke?
Which antiplatelet agents are used for the treatment of middle cerebral artery (MCA) stroke? (medscape.com)